Streetbeat News

Assets

MSTR

MicroStrategy has announced the pricing of an offering of $700 million in 0.625% convertible senior notes due in 2030. This move indicates the company's strategy to raise capital, potentially for further investments or to strengthen its balance sheet.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 1:13 pm

WULF

TeraWulf Inc. (NASDAQ:WULF) announced preliminary FY23 financial results with revenue of $69M, up from $15M in FY22, and a gross profit of $41M, up from $4M in FY22. The company also reported significant debt reduction and cash increase. For FY24, TeraWulf projects strong growth, aiming for industry-leading bitcoin mining unit economics, and plans to expand its infrastructure capacity significantly. The company's strategy focuses on organic growth, debt reduction, and leveraging its zero-carbon energy-powered facilities.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 1:09 pm

WVE

WAVE Life Sciences reported having $200M in cash and cash equivalents as of December 31, 2023. In the first quarter of 2024, the company received an additional $34M from a milestone payment from GSK and the full exercise of the Greenshoe option. This financial boost extends the company's operational runway into the fourth quarter of 2025.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 12:34 pm

ITOS

ITeos Therapeutics (NASDAQ:ITOS) reported Q4 EPS of $(0.85), surpassing the $(1.03) estimate, marking a 257.41% decrease from last year's earnings. The company's cash and investment position of $632.7M is expected to sustain operations through 2026.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 12:26 pm

APLT

Applied Therapeutics announced its current cash and cash equivalents of $49.9M, along with $100M from a February 2024 private placement, are expected to extend its cash runway into the first half of 2026.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 12:24 pm

ADAP

Adaptimmune announced its cash runway extends into early 2026, with over $300M including current cash, expected income from partners, and other non-dilutive capital sources.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 12:15 pm

XERS

Xeris Biopharma projects its 2024 revenue to be between $170M-$200M, aligning with the consensus estimate of $184.11M. The company also forecasts year-end cash, cash equivalents, and short-term investments to range from $55M to $75M.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 12:08 pm

AAPL

GLD

U.S. markets closed lower with major indexes down over 1%, impacted by declines in tech and chip sectors. Economic data showed a drop in U.S. factory orders and ISM services PMI. Apple shares fell due to decreased iPhone sales in China. Asian and European markets were mixed, with commodities like gold trading near lifetime highs amid U.S. rate cut expectations.

Portfolio Pulse from Akanksha Bakshi

March 06, 2024 | 12:08 pm

XERS

Xeris Pharmaceuticals, Inc. has successfully refinanced its $150 million senior secured term loan facility with Hayfin Capital. This strategic financial move is aimed at improving the company's financial flexibility and potentially reducing its cost of capital.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 12:01 pm

BTCUSD

Veteran trader Tone Vays predicts Bitcoin (BTC) could reach $355,000 by April 2027, citing the introduction of spot market ETFs as a key driver. Vays believes breaking the $84,000 to $85,000 threshold will solidify BTC's position above $65,000, marking a significant bullish trend despite recent volatility.

Portfolio Pulse from Benzinga Neuro

March 06, 2024 | 11:55 am